Bristol Myers Squibb (BMY) Cash from Financing Activities (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cash from Financing Activities for 18 consecutive years, with -$2.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 43.25% year-over-year to -$2.6 billion in Q2 2026; TTM through Jun 2026 was -$11.7 billion, a 40.68% decrease from a year earlier, with the FY2025 full-year figure at -$10.3 billion, down 301.83% from the prior year.
• Cash from Financing Activities was -$2.6 billion for Q2 2026 at Bristol Myers Squibb, down from -$1.6 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $14.6 billion in Q1 2024 and troughed at -$6.0 billion in Q4 2025.
• A 5-year average of -$2.0 billion and a median of -$2.8 billion in 2023 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 580.13% in 2024, down 269.8% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$3.2 billion in 2022, then soared by 129.79% to $967.0 million in 2023, then slumped by 269.8% to -$1.6 billion in 2024, then tumbled by 267.17% to -$6.0 billion in 2025, then soared by 56.38% to -$2.6 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$2.6 billion (Q2 2026), -$1.6 billion (Q1 2026), and -$6.0 billion (Q4 2025), per Business Quant data.